Prostate specific antigen and benign prostatic hyperplasia.
Benign prostatic hyperplasia is a common condition in males over 50 years, but prostate cancer can develop in the same population. Prostate specific antigen, the best marker for prostate cancer, is also produced by benign epithelial cells, and there is an overlapping phenomenon between both conditions. The better we understand the relationships between benign prostatic hyperplasia and prostate specific antigen, the higher will be the discrimination power of prostate specific antigen measurement as a marker for prostate cancer. Our scope includes a review of the latest published material to date on this subject.
Laguna
P
P
Urology Department, Hospital Gral. La Mancha-Centro Hospital, Alcazar de San Juan, Spain. mlaguna@hmct.insalud.es
Alivizatos
G
G
D000367:Age Factors; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011467:Prostate / Q000033:anatomy & histology*; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000473:pathology
D015415:Biomarkers; D017430:Prostate-Specific Antigen